Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal

Article Clinical Neurology

Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan

Keisuke Suzuki et al.

Summary: Real-world study confirms the effectiveness and safety of CGRP mAbs in reducing migraine days in patients.

CEPHALALGIA (2023)

添加到收藏夹

Article Clinical Neurology

An observational study on monoclonal antibodies against calcitonin- gene- related peptide and its receptor

Francesca Schiano di Cola et al.

Summary: This study compared the efficacy of anti-CGRP versus anti-CGRP-R monoclonal antibodies in patients with high frequency episodic and chronic migraine. The results showed that the anti-CGRP group had significantly lower migraine days and MIDAS scores compared to the anti-CGRP-R group.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine

Francesco Sacca et al.

Summary: This study compared the effectiveness and safety of galcanezumab, fremanezumab, and erenumab for the treatment of chronic and episodic migraine. The results showed no significant differences between the three antibodies in reducing monthly headache days and MIDAS scores. Additionally, galcanezumab and erenumab had a faster effect than fremanezumab in medication overuse headache patients.

HEADACHE (2023)

添加到收藏夹

Article Clinical Neurology

Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study

Fabrizio Vernieri et al.

Summary: This study evaluated the outcome of migraine patients treated with monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (anti-CGRP) or its receptor (anti-CGRPr). The effectiveness of these mAbs did not differ between the first and second year of treatment. The results suggest that anti-CGRP/CGRPr mAbs are effective in both years.

JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Review Anesthesiology

Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention

Wenfang Sun et al.

Summary: The study evaluated the efficacy and safety of anti-CGRP agents for migraine prevention, finding that monthly fremanezumab 225 mg, monthly erenumab 140 mg, and daily atogepant 60 mg were effective interventions with fewer side effects.

CLINICAL JOURNAL OF PAIN (2023)

添加到收藏夹

Article Clinical Neurology

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

Bianca Raffaelli et al.

Summary: The cessation of CGRP(-receptor) antibodies migraine prophylaxis led to a significant increase in migraine frequency and acute medication intake over time. However, by weeks 13-16, the monthly migraine days were not significantly different from baseline values.

CEPHALALGIA (2022)

添加到收藏夹

Article Clinical Neurology

Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions

Linda Al-Hassany et al.

Summary: Migraine is the second most disabling disorder worldwide, and the pharmacology and clinical effects of CGRP-targeted drugs are not fully understood. Factors such as sex, body-mass index, age, and ethnic background may affect the pharmacokinetics of these treatments, particularly Gepants. Patient characteristics may play a more prominent role in the management of migraine as more is learned about CGRP-targeted therapies.

LANCET NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis

Xing Wang et al.

Summary: This study systematically assessed the comparative effectiveness of different CGRP binding monoclonal antibodies (mAbs) for adult migraine patients with prior treatment failure. The results suggest that CGRP mAbs, especially galcanezumab 240 mg, monthly fremanezumab, and eptinezumab 300 mg, seem to be the best choice for the treatment of migraine patients with previous treatment failures.

JOURNAL OF HEADACHE AND PAIN (2022)

添加到收藏夹

Review Clinical Neurology

Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis

Prashant Soni et al.

Summary: This systematic review and network meta-analysis examined the effects of anti-calcitonin gene related peptide monoclonal antibodies on adult patients with chronic migraine. The results indicated that high doses of subcutaneous fremanezumab and intravenous eptinezumab showed numerical advantages in reducing migraine days. Additionally, anti-CGRP mAbs were found to have comparable safety and immunogenicity, with no significant differences observed.

CLINICAL NEUROLOGY AND NEUROSURGERY (2021)

添加到收藏夹

Article Clinical Neurology

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months

Edoardo Caronna et al.

Summary: In real-life clinical practice, anti-CGRP monoclonal antibodies are effective in chronic migraine patients with medication overuse as well as those without it, leading to a reduction in headache frequency and acute medication use. The choice of different monoclonal antibodies does not affect the resolution of medication overuse, and patients with lower pain severity at baseline are more likely to stop overusing medications.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Clinical Neurology

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Fabrizio Vernieri et al.

Summary: In real-life settings, galcanezumab showed significant effectiveness in preventing HFEM and CM by reducing the number of migraine days and headache intensity, with good safety and tolerability. Patients who responded well to galcanezumab tended to have normal weight and a history of fewer failed preventive treatments.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis

Xing Wang et al.

Summary: The study compared the efficacy of different monoclonal antibodies against CGRP or its receptor for adult patients with migraine, showing that most drugs performed similarly and were superior to placebo in terms of efficacy, but galcanezumab had slightly different safety profile.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Review Clinical Neurology

Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine

Min Shi et al.

Summary: Studies show that anti-CGRP monoclonal antibodies are effective for treating episodic migraines. The comparison of different treatment regimens suggests that Fremanezumab (225 mg) and Galcanezumab (120 mg) may be the best clinical protocols.

NEUROLOGICAL RESEARCH (2021)

添加到收藏夹

Review Pharmacology & Pharmacy